公开(公告)号：US12209072B2

公开(公告)日：2025-01-28

申请号：US17276176

申请日：2019-09-16

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter Tai Wah Cheng ,  Robert F. Kaltenbach, III ,  Jun Shi ,  Yan Shi ,  Hao Zhang

IPC: C07D261/08 ,  C07D249/06 ,  C07D401/04 ,  C07D403/04 ,  C07D413/04 ,  C07D413/14

Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US20240262799A1

公开(公告)日：2024-08-08

申请号：US18420478

申请日：2024-01-23

Applicant: IL DONG PHARMACEUTICAL CO., LTD.

Inventor： Jae-Hoon KANG ,  Hong-Sub LEE ,  Yoon-Suk LEE ,  Jin-Ah JEONG ,  Sung-Wook KWON ,  Jeong-Guen KIM ,  Kyung-Sun KIM ,  Dong-Keun SONG ,  Sun-Young PARK ,  Kyeo-Jin KIM ,  Ji-Hye CHOI ,  Hey-Min HWANG

IPC: C07D261/08

CPC classification number: C07D261/08

Abstract: Disclosed are methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, disorder of bile acid homeostasis, or organ fibrosis, which includes administering to a subject a therapeutically effective amount of a pharmaceutical composition containing an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.

公开(公告)号：US20240025858A1

公开(公告)日：2024-01-25

申请号：US18257373

申请日：2021-12-15

Applicant: GW Research Limited

Inventor： Alan James SILCOCK ,  Antoine MILLET ,  Karen Ka-Yen TSE ,  Paul Stuart HINCHLIFFE ,  Andrew SHARPE ,  Iain David SIMPSON ,  Joanne PEACH ,  Stefano LEVANTO

IPC: C07D231/12 ,  C07C39/23 ,  C07D249/06 ,  C07D239/34 ,  C07D213/65 ,  C07D213/74 ,  C07D213/16 ,  C07D213/14 ,  C07D405/04 ,  C07D263/32 ,  C07D249/08 ,  C07D261/08 ,  C07D233/64 ,  C07D271/10 ,  C07D213/64 ,  C07D405/06 ,  C07C215/50 ,  C07C213/08 ,  C07C43/23 ,  C07C41/30 ,  C07D271/06 ,  A61P25/08

CPC classification number: C07D231/12 ,  C07C39/23 ,  C07D249/06 ,  C07D239/34 ,  C07D213/65 ,  C07D213/74 ,  C07D213/16 ,  C07D213/14 ,  C07D405/04 ,  C07D263/32 ,  C07D249/08 ,  C07D261/08 ,  C07D233/64 ,  C07D271/10 ,  C07D213/64 ,  C07D405/06 ,  C07C215/50 ,  C07C213/08 ,  C07C43/23 ,  C07C41/30 ,  C07D271/06 ,  A61P25/08

Abstract: The present invention relates to a group of novel compounds, methods for their manufacture and the use of these compounds as research tools and as pharmaceuticals. The novel compounds are analogues of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of novel cannabidiol compounds.

公开(公告)号：US11806337B2

公开(公告)日：2023-11-07

申请号：US17875216

申请日：2022-07-27

Applicant: Sanford Burnham Prebys Medical Discovery Institute

Inventor： Stephen Gardell ,  Anthony B. Pinkerton ,  Eduard Sergienko ,  Hampton Sessions

IPC: A61K31/4409 ,  A61K31/196 ,  A61K31/245 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/417 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/422 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4418 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/5386 ,  C07C275/42 ,  C07D213/40 ,  C07D213/56 ,  C07D213/643 ,  C07D213/73 ,  C07D213/74 ,  C07D231/12 ,  C07D233/64 ,  C07D237/08 ,  C07D239/26 ,  C07D249/04 ,  C07D261/08 ,  C07D263/32 ,  C07D277/28 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D498/08

CPC classification number: A61K31/4409 ,  A61K31/196 ,  A61K31/245 ,  A61K31/415 ,  A61K31/417 ,  A61K31/4155 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/422 ,  A61K31/426 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4355 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/443 ,  A61K31/444 ,  A61K31/4406 ,  A61K31/4418 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/5386 ,  C07C275/42 ,  C07D213/40 ,  C07D213/56 ,  C07D213/643 ,  C07D213/73 ,  C07D213/74 ,  C07D231/12 ,  C07D233/64 ,  C07D237/08 ,  C07D239/26 ,  C07D249/04 ,  C07D261/08 ,  C07D263/32 ,  C07D277/28 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D498/08

Abstract: Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.

公开(公告)号：US20230286904A1

公开(公告)日：2023-09-14

申请号：US18013431

申请日：2021-07-02

Applicant: BRIDGENE BIOSCIENCES, INC.

Inventor： Chao ZHANG ,  Michael J. BISHOP ,  Hang CHEN ,  Ping CAO

IPC: C07C233/25 ,  A61K45/06 ,  C07C233/27 ,  C07C251/42 ,  C07D333/32 ,  C07D333/36 ,  C07D213/643 ,  C07D311/68 ,  C07D215/38 ,  C07D213/64 ,  C07D261/08 ,  C07D231/12 ,  C07D231/54 ,  C07D261/20 ,  C07D271/06 ,  C07D249/06 ,  C07D309/14 ,  C07D261/12 ,  C07D217/24 ,  C07D213/40 ,  C07D237/08 ,  C07D275/02 ,  C07D205/04 ,  C07C233/23

CPC classification number: C07C233/25 ,  A61K45/06 ,  C07C233/23 ,  C07C233/27 ,  C07C251/42 ,  C07D205/04 ,  C07D213/40 ,  C07D213/64 ,  C07D213/643 ,  C07D215/38 ,  C07D217/24 ,  C07D231/12 ,  C07D231/54 ,  C07D237/08 ,  C07D249/06 ,  C07D261/08 ,  C07D261/12 ,  C07D261/20 ,  C07D271/06 ,  C07D275/02 ,  C07D309/14 ,  C07D311/68 ,  C07D333/32 ,  C07D333/36 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2602/50

Abstract: Disclosed herein are synthesis and use of covalent inhibitors selective for Transcriptional Enhancer Factor TEF-1 (TEAD1), which can be used for treatment of cancers such as glioblastoma, gastric cancer, colorectal cancer, pancreatic ductal adenocarcinoma (PDAC), and malignant pleural mesothelioma (MPM). Further disclosed herein are pharmaceutical compositions including the TEAD1 inhibitor and methods of treating cancers using the same.

公开(公告)号：US11679093B2

公开(公告)日：2023-06-20

申请号：US17251070

申请日：2019-06-11

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

Inventor： Kambez Hajipouran Benam

IPC: C07C257/18 ,  A61K31/167 ,  A61K31/472 ,  A61K31/4725 ,  C07D217/26 ,  C07D217/12 ,  A61K31/245 ,  A61K31/194 ,  A61K31/195 ,  A61K31/4166 ,  A61K31/42 ,  A61K31/422 ,  A61K45/06 ,  C07C279/18 ,  C07D233/70 ,  C07D261/08

CPC classification number: A61K31/245 ,  A61K31/167 ,  A61K31/194 ,  A61K31/195 ,  A61K31/4166 ,  A61K31/42 ,  A61K31/422 ,  A61K45/06 ,  C07C257/18 ,  C07C279/18 ,  C07D233/70 ,  C07D261/08

Abstract: The present invention relates in certain aspects to the discovery of novel 2-naphthimidamide compounds that are capable of binding Type II Transmembrane Serine Proteases (TTSPs). In certain embodiments, the compounds of the invention can be used to treat or prevent Influenza A viral infection in a mammal.

公开(公告)号：US20230172206A1

公开(公告)日：2023-06-08

申请号：US17920797

申请日：2021-04-15

Applicant: BASF SE

Inventor： Andreas Koch ,  Marcus Fehr ,  Vanessa Tegge ,  Chandan Dey ,  Manojkumar Poonoth ,  Sarang Kulkarni ,  Ronan Le Vezouet ,  Christian Harald Winter ,  Georg Christoph Rudolf ,  Rakesh Rath ,  Smriti Khanna ,  lan Robert Craig ,  Wassilios Grammenos ,  Thomas Grote ,  Gerd Stammler ,  Tobias Mentzel ,  Egon Haden ,  Joachim Rheinheimer

IPC: A01N37/50 ,  C07C251/60 ,  C07D205/04 ,  C07D261/08 ,  C07C255/64 ,  C07D271/06 ,  C07D305/06 ,  C07D277/28 ,  A01N37/18 ,  A01N43/44 ,  A01N43/80 ,  A01N37/34 ,  A01N43/82 ,  A01N43/20 ,  A01N43/78 ,  A01N37/36 ,  A01P3/00

CPC classification number: A01N37/50 ,  A01N37/18 ,  A01N37/34 ,  A01N37/36 ,  A01N43/20 ,  A01N43/44 ,  A01N43/78 ,  A01N43/80 ,  A01N43/82 ,  A01P3/00 ,  C07C251/60 ,  C07C255/64 ,  C07D205/04 ,  C07D261/08 ,  C07D271/06 ,  C07D277/28 ,  C07D305/06 ,  C07C2601/02

Abstract: The present invention relates to the use of strobilurin type compounds of formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein (also referred to as F129L mutation in the mitochondrial cytochrome b gene) conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, and to seeds coated with at least one such compound.

公开(公告)号：US20230159438A1

公开(公告)日：2023-05-25

申请号：US17832384

申请日：2022-06-03

Applicant: Genzyme Corporation

Inventor： Junkai Liao ,  Mark Munson ,  Zhongli Gao ,  Gregory Hurlbut ,  Hans Peter Nestler ,  Helen Yeoman ,  Martin Smrcina ,  Ronghua Li ,  Ryan Hartung ,  William Wire ,  Bertrand Vivet ,  Nina Ma

IPC: C07C235/66 ,  C07D231/12 ,  C07D317/54 ,  C07C317/14 ,  C07C321/28 ,  C07D277/24 ,  C07D213/30 ,  C07D261/08 ,  C07D277/64 ,  C07D277/30 ,  C07D305/06 ,  A61K31/198 ,  A61K31/415 ,  A61K31/36 ,  A61K31/426 ,  A61K31/44 ,  A61K31/42 ,  A61K31/428 ,  A61K31/337 ,  A61K45/06

CPC classification number: C07C235/66 ,  C07D231/12 ,  C07D317/54 ,  C07C317/14 ,  C07C321/28 ,  C07D277/24 ,  C07D213/30 ,  C07D261/08 ,  C07D277/64 ,  C07D277/30 ,  C07D305/06 ,  A61K31/198 ,  A61K31/415 ,  A61K31/36 ,  A61K31/426 ,  A61K31/44 ,  A61K31/42 ,  A61K31/428 ,  A61K31/337 ,  A61K45/06 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2602/10

Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

公开(公告)号：US20230142508A1

公开(公告)日：2023-05-11

申请号：US17991792

申请日：2022-11-21

Applicant: The Broad Institute, Inc. ,  The General Hospital Corporation ,  Instituto Carlos Slim de la Salud, A.C.

Inventor： Sean M. Burns ,  Bridget K. Wagner ,  Amedeo Vetere

IPC: C07D413/12 ,  A61P3/08 ,  C07C235/84 ,  C07D213/30 ,  C07D231/12 ,  C07D237/08 ,  C07D261/08 ,  C07D495/04

CPC classification number: C07D413/12 ,  A61P3/08 ,  C07C235/84 ,  C07D213/30 ,  C07D231/12 ,  C07D237/08 ,  C07D261/08 ,  C07D495/04

Abstract: Disclosed herein are methods for inducing insulin secretion in a glucose-dependent manner and compounds for use in these methods.

公开(公告)号：US20230116770A1

公开(公告)日：2023-04-13

申请号：US17875216

申请日：2022-07-27

Applicant: Sanford Burnham Prebys Medical Discovery Institute

Inventor： Stephen GARDELL ,  Anthony B. PINKERTON ,  Eduard SERGIENKO ,  Hampton SESSIONS

IPC: A61K31/4409 ,  A61K31/196 ,  A61K31/245 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/417 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/422 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4418 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/5386 ,  C07C275/42 ,  C07D213/40 ,  C07D213/56 ,  C07D213/643 ,  C07D213/73 ,  C07D213/74 ,  C07D231/12 ,  C07D233/64 ,  C07D237/08 ,  C07D239/26 ,  C07D249/04 ,  C07D261/08 ,  C07D263/32 ,  C07D277/28 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D498/08

Abstract: Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.